Narayana Hrudayalaya Ltd. (NH)

Healthcare · Healthcare Services · NSE · Updated 3 August 2026
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
₹1,919.7 ↑ 0.23% (1Y)

🎯 Key Takeaways

  • Narayana Hrudayalaya Ltd. is transitioning from a mature healthcare services operator into a high-growth phase driven by strategic capex and digital transformation, evidenced by a 78% YoY revenue surge in Q1 FY27 to ₹26,836 Mn and expansion into new facilities like the HSR Bangalore hospital targeting FY28 completion.
  • Revenue declined 2.4% QoQ to ₹1,367 in Q3FY25.
  • ⚠️ Elevated net debt of ₹19,671 Mn poses financial risk if capex does not translate into sustained revenue growth. Execution delays in the HSR Bangalore
Market Cap
₹37,625
P/E Ratio
47.7
Div Yield
0.00%
Promoter
0.0%

📖 The Story

Narayana Hrudayalaya Ltd. is transitioning from a mature healthcare services operator into a high-growth phase driven by strategic capex and digital transformation, evidenced by a 78% YoY revenue surge in Q1 FY27 to ₹26,836 Mn and expansion into new facilities like the HSR Bangalore hospital targeting FY28 completion. The company is actively investing in capacity and ESG infrastructure while maintaining stable promoter control, signaling a deliberate shift toward scalable, technology-enabled healthcare delivery.

📰 What's Happening

In Q1 FY27, the company reported robust top-line growth to ₹26,836 Mn (+78% YoY) with EBITDA margin expanding to 18.8% and PAT at ₹2,073 Mn. Management highlighted the transfer of a hospital to a charitable trust, incorporation of a new subsidiary, and initiation of capex for a 215-bed greenfield hospital in HSR Bangalore. Digital initiatives contributed to a 50% reduction in patient incidents and 4 million app installs. The board re-appointed an independent director and declared a final dividend of ₹4.50 per share. The earnings call for Q1 FY26 was made accessible via audio recording on August 3, 2026, per regulatory requirements.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

MetricQ4FY23Q1FY24Q2FY24Q3FY24Q4FY24Q1FY25Q2FY25Q3FY25
Revenue1,2221,2331,3051,2041,2791,3411,4001,367
Operating Profit290286327297318327332325
OPM %22.6%21.9%23.6%23.2%23.0%22.7%22.0%22.5%
Net Profit173184227188191201199193
EPS₹8.53₹9.06₹11.16₹9.26₹9.39₹9.92₹9.78₹9.50

Quarterly revenue has shown consistent upward momentum, rising from ₹1,222 Cr in Q4FY23 to ₹1,367 Cr in Q3FY25, with operating margins holding steady around 22-23% despite inflationary pressures. Net profit and EPS have remained stable, indicating operational resilience. This growth trajectory aligns with management's disclosed capex plans and digital adoption, suggesting scalable profitability without margin erosion from volume-driven expansion.

🔮 Management Outlook & What's Next

Management has articulated forward-looking ESG and expansion targets, including completion of the HSR Bangalore hospital by FY28 and achieving 50% renewable energy usage by 2030, building on current 39.08% renewable electricity consumption. These goals are reinforced in the BRSR filing and annual report disclosures, reflecting a long-term strategy integrating sustainability with operational scaling. No specific financial guidance was provided in recent filings, but operational targets are clearly linked to strategic investments.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Healthcare Services

Company MCap (₹ Cr) P/E ROCE ROE D/E
Apollo Hospitals Enterprise Limited 1.16 L Cr 64.5 20.5% 21.9% 0.64
Max Healthcare Institute Limited 1.02 L Cr 101.2
Fortis Healthcare Limited 72,752 94.6
Aster DM Healthcare Limited 39,048 7.1
Narayana Hrudayalaya Ltd. 37,625 47.7
Global Health Limited 33,405 65.8
Krishna Institute of Medical Sciences Limited 30,477 80.3
Dr. Lal Path Labs Ltd. 26,871 63.6
Syngene International Limited 18,295 36.3
Dr. Agarwal's Health Care Limited 14,266 88.8 14.9% 6.8% 0.13

🔗 Peer Stock Analyses

⚠️ Risk Factors

Elevated net debt of ₹19,671 Mn poses financial risk if capex does not translate into sustained revenue growth. Execution delays in the HSR Bangalore hospital or underperformance of digital initiatives could pressure margins. Regulatory and compliance risks remain, particularly around ESG target delivery by 2030 and 2040, which require ongoing capital and operational discipline. Additionally, the company's reliance on hospital network expansion exposes it to execution and market saturation risks.

📋 Recent Filings

🧠 Analyst's Read

Narayana Hrudayalaya is executing a clear growth strategy backed by capital investment and digital innovation, with improving operational metrics supporting scalability. Investors should monitor the progress of the HSR Bangalore hospital completion by FY28 and the pace of renewable energy adoption, as these will be key indicators of long-term strategic execution and sustainability resilience.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

Sign Up Free — Unlock Full Analysis

2 free AI queries per day.

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-08-03.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when NH files new disclosures

Track NH filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track NH — Free

Free account · 2 AI queries/day